European International Journal of Multidisciplinary Research and Management Studies (ISSN: 2750-8587)

Received: 04 July 2026 | Accepted: 06 August 2026 | Published: 31 August 2026

DOI: 10.55640/eijmrms-06-08-04

RESEARCH ARTICLE

Innovative Approaches to The Development of Prolonged-Release Dosage Forms

Kocherova Umida Anvarovna

4th-year Student, Faculty of Dentistry and Pharmacy, Pharmacy Program, Alfraganus University, Tashkent, Uzbekistan

Usmonova Malika Komiljonovna

Acting Associate Professor (PhD), Department of Pharmaceutical Sciences and Chemistry, Alfraganus University, Tashkent, Uzbekistan

VOLUME: Vol.06 Issue08 2026

PAGE: 30-33

Abstract

Prolonged-release dosage forms are an important direction of modern pharmaceutical technology because they are designed to release an active pharmaceutical ingredient at a controlled rate for an extended period. Compared with conventional immediate-release medicines, prolonged-release systems can reduce dosing frequency, decrease fluctuations in drug concentration, and support better adherence to therapy. This article reviews contemporary technological approaches used in the development of prolonged-release dosage forms, with emphasis on matrix tablets, polymeric coatings, multiparticulate systems, osmotic systems, lipid-based carriers, and emerging technologies such as hot-melt extrusion and three-dimensional printing. The mechanisms of drug release, selection of excipients, manufacturing principles, quality control, advantages, limitations, and future prospects are discussed. A quality-by-design approach is also considered as an important framework for linking formulation and process variables with critical quality attributes. Modern technologies increasingly allow formulators to tailor release profiles to the physicochemical properties of active substances and the therapeutic requirements of patients. Nevertheless, reproducibility, dose dumping, stability, scale-up, regulatory requirements, and reliable in vivo–in vitro correlations remain important challenges. The development of prolonged-release medicines therefore requires an integrated combination of pharmaceutics, material science, process engineering, analytical control, and clinical considerations.

KEYWORDS

Prolonged-release dosage forms; modified drug release; matrix tablets; controlled release; pharmaceutical technology; polymers; osmotic systems; hot-melt extrusion; 3D printing; quality by design.

INTRODUCTION

Oral drug delivery remains one of the most widely used approaches for administering medicines because it is convenient, non-invasive, economical, and generally well accepted by patients. However, conventional immediate-release dosage forms may produce rapid changes in plasma drug concentrations. For medicines with short elimination half-

lives, repeated administration may be required to maintain therapeutic exposure. Such regimens can increase the risk of missed doses and may contribute to peak-related adverse effects and subtherapeutic trough concentrations.

Prolonged-release dosage forms are developed to modify the rate at which an active pharmaceutical ingredient becomes available for absorption. Their purpose is not simply to delay drug release, but to provide a more sustained exposure over a defined period. Extended-release, sustained-release, and other modified-release concepts are therefore important tools in pharmaceutical formulation. Properly designed systems may simplify dosing schedules and improve the consistency of pharmacological action. The development of these products requires consideration of drug solubility, permeability, dose, half-life, absorption window, stability, therapeutic index, and interaction with excipients. ICH pharmaceutical development principles emphasize the identification of critical quality attributes and the relationship between material attributes, process parameters, and product performance.

Drug release from a prolonged-release dosage form can be controlled through several physical and chemical mechanisms. The principal mechanisms include diffusion, dissolution, swelling and erosion of polymeric matrices, osmotic pressure, ion exchange, and combinations of these processes. The selected mechanism must be compatible with the physicochemical characteristics of the drug and the intended therapeutic profile. Diffusion-controlled systems use a polymeric barrier or matrix through which dissolved drug molecules gradually move. In hydrophilic matrices, water penetrates the dosage form and causes polymer hydration and swelling. A gel layer can then form around the tablet, creating a barrier to drug diffusion. In hydrophobic matrices, the drug is dispersed within a water-insoluble material and is released through pores and channels created during hydration and dissolution. Dissolution-controlled systems depend on the gradual dissolution of a coating or carrier. By changing coating thickness, polymer properties, particle size, or formulation composition, the release rate can be adjusted. Osmotic systems use water influx and osmotic pressure to push dissolved drug through a controlled outlet. Such systems can provide relatively predictable release under appropriate conditions.

Matrix tablets are among the most practical and widely investigated prolonged-release dosage forms. They can be manufactured using direct compression, wet granulation, dry granulation, or other conventional tablet technologies. Their main advantage is that the release-modifying polymer can be incorporated directly into the tablet matrix. Hydrophilic polymers such as hydroxypropyl methylcellulose are commonly used because they hydrate after contact with gastrointestinal fluid and form a viscous gel layer. The thickness and properties of this layer influence penetration of liquid, drug dissolution, diffusion, and matrix erosion. Hydrophobic materials can also be employed when slower release is required. The final release profile depends on polymer concentration and grade, drug solubility, tablet porosity, compression force, drug-to-polymer ratio, particle size, and other formulation variables. Therefore, formulation optimization is essential. A successful matrix system should provide reproducible release without premature dose dumping or excessive retention of drug in the matrix.

Coated tablets, pellets, granules, and microspheres provide another important strategy for prolonging drug release. A functional polymeric membrane can act as a diffusion barrier around drug-containing particles. The release rate can be adjusted through polymer type, coating thickness, plasticizer concentration, pore-forming agents, and coating process conditions. Multiparticulate systems have particular technological value because the dose is distributed among numerous small units. After administration, these units can disperse throughout the gastrointestinal tract, potentially reducing the dependence of drug release on the behavior of a single tablet. Combining immediate-release and prolonged-release populations can also create biphasic or programmable release profiles. Film coating technologies have developed considerably and can now be integrated with aqueous polymer dispersions, fluidized-bed processing, and precision coating approaches. However, uniformity of coating is critical because local defects or variations in membrane thickness can alter the release profile significantly.

Osmotic drug delivery systems are designed to use osmotic pressure as the driving force for drug release. A semipermeable membrane controls water entry, while an osmotic core generates pressure that promotes controlled drug delivery through a small orifice. These systems can offer a high degree of control and are particularly attractive for drugs requiring consistent release. Gastroretentive and site-specific systems represent additional approaches. Floating

dosage forms can be designed to remain in the stomach for a prolonged period, while mucoadhesive systems seek to increase contact with gastrointestinal mucosa. pH-responsive polymers may delay drug release until the formulation reaches a desired intestinal region. Such strategies must account for physiological variability, gastrointestinal motility, food effects, and differences between patients.

Modern pharmaceutical technology increasingly incorporates advanced manufacturing methods. Hot-melt extrusion can combine an active ingredient with thermoplastic polymers and produce continuous matrices or solid dispersions. The method can improve process efficiency and allow control over drug distribution and release characteristics when the drug and polymer are thermally compatible. Three-dimensional printing is another emerging approach. By changing the geometry, infill density, internal architecture, and composition of a printed dosage form, drug release can potentially be programmed more precisely. 3D printing is particularly interesting for personalized medicines and multi-drug products in which different active ingredients may require different release rates. Other technologies, including electrospinning, spray drying, microfluidic processing, and advanced coating systems, may provide additional control over particle structure, polymer organization, and drug distribution. These technologies are promising but require careful assessment of scalability, equipment cost, reproducibility, regulatory acceptance, and manufacturing robustness.

Quality by Design (QbD) provides a systematic framework for pharmaceutical development. It begins with a quality target product profile and identifies critical quality attributes that must be controlled to ensure consistent product performance. In prolonged-release products, dissolution behavior, assay, content uniformity, mechanical properties, stability, and release kinetics are particularly important. Risk assessment can be used to connect critical material attributes and critical process parameters with product quality. Design of experiments can then help identify significant formulation variables and their interactions. This approach can reduce trial-and-error development and improve understanding of how formulation composition and manufacturing conditions affect release behavior. For prolonged-release medicines, dissolution testing is especially important. The test should be capable of distinguishing meaningful changes in formulation or process conditions. Mathematical models such as zero-order, first-order, Higuchi, and Korsmeyer–Peppas models may be used to help interpret release mechanisms, although model selection should be scientifically justified.

The major therapeutic advantage of prolonged-release systems is the possibility of maintaining drug exposure for longer periods while reducing administration frequency. This may improve patient convenience and adherence, particularly in chronic therapy. Reduced peak–trough fluctuations may also improve tolerability for selected medicines. From a pharmaceutical perspective, prolonged-release technology can provide flexibility in designing drug delivery profiles. Formulators may combine polymers, coatings, multiparticulates, and other mechanisms to produce release patterns tailored to a particular drug. In some cases, prolonged delivery can also reduce the frequency of administration during sleep or other periods when adherence may be difficult.

Despite their advantages, prolonged-release dosage forms are not appropriate for every active pharmaceutical ingredient. Drugs with very short absorption windows, very high required doses, unsuitable pharmacokinetic characteristics, or highly variable gastrointestinal absorption may be difficult to formulate successfully. The formulation may also become more sensitive to physiological factors such as food intake, gastrointestinal transit, and pH. A major safety concern is dose dumping, in which a large fraction of the drug is released more rapidly than intended. This can occur because of formulation defects, inappropriate excipient selection, alcohol interactions in some systems, or mechanical damage to the dosage form. Stability of the polymer and maintenance of release performance throughout shelf life are also important. Scale-up from laboratory to industrial production may change granule properties, tablet porosity, coating uniformity, thermal history, or mixing efficiency. Therefore, process understanding and appropriate in-process controls are essential. Regulatory evaluation additionally requires robust evidence that the product consistently meets predefined quality specifications.

The future of prolonged-release pharmaceutical technology is likely to involve greater integration of materials science, computational modeling, personalized medicine, and advanced manufacturing. Artificial intelligence and mechanistic modeling may assist in predicting formulation behavior and identifying promising combinations of polymers and process conditions. Personalized prolonged-release

systems may allow the dose and release rate to be adapted to individual pharmacokinetic requirements. 3D printing and digitally controlled manufacturing are particularly attractive in this context because they can provide greater flexibility in dosage-form architecture. At the same time, sustainable manufacturing and safer excipients are becoming increasingly relevant to pharmaceutical development. Future research should also focus on stronger in vitro–in vivo correlations, robust scale-up strategies, and standardized evaluation of advanced release systems. Successful innovation will depend not only on achieving a desirable dissolution curve but also on demonstrating reproducible product quality, stability, safety, and therapeutic benefit.

CONCLUSION

Prolonged-release dosage forms represent a major area of pharmaceutical technology for improving the delivery of medicines over extended periods. Matrix tablets, polymeric coatings, multiparticulate systems, osmotic technologies, and site-specific approaches provide several mechanisms for controlling drug release. Recent developments in hot-melt extrusion, 3D printing, and other advanced manufacturing technologies are expanding the ability to design more precise and adaptable dosage forms. The successful development of a prolonged-release medicine requires an integrated understanding of drug properties, excipient functionality, manufacturing processes, release mechanisms, and quality control. Quality-by-design principles can strengthen this process by linking formulation and process variables to critical quality attributes. Although challenges such as dose dumping, physiological variability, scale-up, and regulatory validation remain, continued technological progress is expected to make prolonged-release systems more precise, patient-centered, and adaptable to modern therapeutic needs.

REFERENCES

1. International Council for Harmonisation (ICH). Q8(R2): Pharmaceutical Development. ICH Harmonised Guideline.
2. Aulton M.E., Taylor K.M.G. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. Elsevier.
3. Allen L.V., Ansel H.C. Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Wolters Kluwer.
4. Remington: The Science and Practice of Pharmacy. Pharmaceutical Press.
5. Brahmankar D.M., Jaiswal S.B. Biopharmaceutics and Pharmacokinetics: A Treatise. Vallabh Prakashan.
6. Qiu Y., Chen Y., Zhang G.G.Z., Yu L., Mantri R.V. Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice. Academic Press.
7. Adejare A. Remington: Essentials of Pharmaceutics. Pharmaceutical Press.
8. Atre P., Rizvi S.A.A. Advances in Oral Solid Drug Delivery Systems: Quality by Design Approach in Development of Controlled Release Tablets. BioChem. 2025;5(2):9.
9. Drapińska P., Skulmowska-Polok K., Chałupka J., Sikora A. Sustained-Release Oral Delivery of NSAIDs and Acetaminophen: Advances and Recent Formulation Strategies—A Systematic Review. Pharmaceutics. 2025;17(10):1264.
10. Lieberman H.A., Lachman L., Schwartz J.B. Pharmaceutical Dosage Forms: Tablets. Marcel Dekker.